Although numerous somatic mutations have been identified in IDH1/2 in tumors [691,692], there appears to be a predilection for specific binding site “hotspot” mutations (Arg 132 for IDH1, Arg 172 for IDH2) in certain diseases such as leukemia and glioma. This evidence concerns the gene IDH1 and central nervous system cancer.